ReviewCurrent cardiology reports2021
Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
Review in Current cardiology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Targeting Cell Signalling Pathways with New Small Molecules in Inflammation and Cancer.Current topics in medicinal chemistry · 2026Review
- Effect of chemotherapy and different chemotherapeutic regimens on electrocardiographic parameters in breast cancer women: a retrospective and within-subject longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Cardiovascular disease in breast cancer patients: a nationwide real-world evidence study 2013-20.European heart journal open · 2025Article
- Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review.Frontiers in cardiovascular medicine · 2025Article
- Risk Factors for Death from Heart Disease in Elderly Colon Cancer Patients with Liver Metastasis.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Cardiovascular Disease Incidence and Cardiovascular Health Among Diverse Women With Breast and Gynecologic Cancers.Oncology nursing forum · 2024Article
- MRI-Conditional Breast Tissue Expander: First In-Human Multi-Case Assessment of MRI-Related Complications and Image Quality.Journal of clinical medicine · 2023Article
- Routine first-line detection of breast cancer therapy-related cardiotoxicity by serial, fast and ultra-low-dose equilibrium radionuclide angiography.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Drug therapy for myocarditis induced by immune checkpoint inhibitors.Frontiers in pharmacology · 2023Review
- Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer.Frontiers in oncology · 2022Review
- Quantifying Societal Burden of Radiation-Induced Cardiovascular Events in Breast Cancer Survivors.Frontiers in oncology · 2022Article
- Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.Current heart failure reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCardiotoxicity can occur acutely during breast cancer treatment and impact the potential for the intended cancer treatment regime to be completed, or as a late effect affecting cancer survivorship. Indeed, the most common cause of mortality in females with early breast cancer is cardiovascular disease, especially in those over the age of 65. Optimal cancer care therefore needs to be delivered without jeopardising cardiovascular health. Understanding the different cardiotoxicities associated with breast cancer treatment is vital to this approach, and therefore, this article seeks to provide an overview of this. RECENT
findingsTyrosine kinase inhibitors targeting human epidermal growth factor receptor (HER)-2, immune checkpoint inhibitors (ICI), and cyclin-dependent kinase (CDK) inhibitors are new targeted breast cancer treatments. In particular, ICI are associated with myocarditis that carries a significant mortality, whilst the CDK inhibitor ribociclib causes QT prolongation that requires cardiac surveillance and appropriate dose adjustment to prevent ventricular arrhythmias. The need has always been for strategies to mitigate the risks of cardiovascular toxicities, and new data is promising for the use of dexrazoxane in anthracyclines, and the role of beta blockers and angiotensin converting enzymes inhibitors in anthracyclines and HER-2 monoclonal antibodies such as trastuzumab. Significant headways in breast cancer treatment have resulted in reductions in disease recurrence and mortality, but cardiovascular complications continue to impact the ability to deliver some of these cancer treatments, and the period of cancer survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.